Drug Profile
Research programme: neurodegenerative disorder therapeutics - Oncodesign/UCB
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Oncodesign Biotechnology
- Developer Oncodesign Biotechnology; UCB
- Class Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders